Skip to main content

Advertisement

SpringerLink
Log in

Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

In vitro data suggest that myokine irisin may affect bone metabolism by promoting osteoblast differentiation while inhibiting osteoclast differentiation. In this study, circulating irisin levels were associated with previous osteoporotic fractures but not with bone mass and were not affected by denosumab or teriparatide treatment for 3 months.

Introduction

This study aimed to evaluate predictors of circulating irisin in postmenopausal women with low bone mass and to assess a potential effect of denosumab or teriparatide treatment for 3 months.

Methods

Serum samples for irisin measurement were obtained from (a) postmenopausal women with low bone mass (lumbar spinal [LS] or femoral neck [FN] bone mineral density [BMD] T-score ≤−2.0) and their age-matched controls at baseline and 3 months after denosumab (Dmab) injection (Dmab group, n = 50; Dmab control group, n = 25) and (b) women with more severe disease (LS or FN BMD T-score ≤−2.8) and their age-matched controls at the above-mentioned time points after teriparatide (TPTD) initiation (TPTD group, n = 25; TPTD control group, n = 25).

Results

At baseline, irisin levels were inversely correlated with age (partial coefficient (r p ) = −0.24; p = 0.009), parathyroid hormone (PTH) (r p  = −0.30; p = 0.001), and creatinine (r p  = −0.23; p = 0.016) in univariate analysis, and were lower in women with (n = 26; 41.6 ± 2.7 ng/dL) than without previous osteoporotic fracture(s) (n = 99; 51.0 ± 1.6 ng/dL; p = 0.007). In multiple linear regression, previous osteoporotic fracture(s) and PTH were independently negatively associated with irisin [p = 0.04, CI −16.1 to −0.4 and p = 0.002, CI −0.3 to −0.07, respectively], but only the association with PTH remained after controlling for creatinine levels. Serum irisin levels were not different between women with or without low bone mass and were not affected by either Dmab or TPTD treatment for 3 months.

Conclusions

Circulating irisin levels were associated with previous osteoporotic fracture(s); whether this association is independent or is due to confounding by lower muscle mass, potentially reflected by lower creatinine levels, remains to be fully clarified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018

    Article  CAS  PubMed  Google Scholar 

  2. Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P (2012) Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag 8:295–306

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Hodsman A, Bauer D, Dempster D et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703

    Article  CAS  PubMed  Google Scholar 

  4. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465

    Article  CAS  PubMed  Google Scholar 

  5. Boström P, Wu J, Jedrychowski MP et al (2012) A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468

    Article  PubMed Central  PubMed  Google Scholar 

  6. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725–1738

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Staiger H, Böhm A, Scheler M et al (2013) Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived ‘browning’ factor irisin, determines insulin sensitivity. PLoS One 8:e61903

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Polyzos SA, Kountouras J, Shields K, Mantzoros CS (2013) Irisin: a renaissance in metabolism? Metabolism 62:1037–1044

    Article  CAS  PubMed  Google Scholar 

  9. Rahman S, Lu Y, Czernik PJ, Rosen CJ, Enerback S, Lecka-Czernik B (2013) Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology 154(8):2687–2701

    Article  CAS  PubMed  Google Scholar 

  10. Zhang J, Wu Y, Yu L, Meng S, Zhang L, Huang M, Tu Q, Chen JJ (2012) Exercise strengthens bone through myokine irisin. J Bone Miner Res 27 (Suppl 1). Available at http://www.asbmr.org/Itinerary/PresentationDetail.aspx?id=a8a0e3b4-1ca5-4b3e-b35a-307b043e1458. Accessed 14–15 October 2012

  11. DiVasta AD, Gordon CM (2013) Exercise and bone: where do we stand? Metabolism 62:1714–1717

    Article  CAS  PubMed  Google Scholar 

  12. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernández-Real JM (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769–E778

    Article  CAS  PubMed  Google Scholar 

  13. Wen MS, Wang CY, Lin SL, Hung KC (2013) Decrease in irisin in patients with chronic kidney disease. PLoS One 8:e64025

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Ensrud KE, Ewing SK, Fredman L, Hochberg MC, Cauley JA, Hillier TA, Cummings SR, Yaffe K, Cawthon PM, Group SoOFR (2010) Circulating 25-hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab 95:5266–5273

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Murad MH, Elamin KB, Abu Elnour NO et al (2011) Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:2997–3006

    Article  CAS  PubMed  Google Scholar 

  16. Makras P, Polyzos SA, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis AD (2013) Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 79:499–503

    Article  CAS  Google Scholar 

  17. Anastasilakis AD, Polyzos SA, Goulis DG, Slavakis A, Efstathiadou Z, Kita M, Koukoulis G, Avramidis A (2008) Endogenous intact PTH is suppressed during teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis. Endocr J 55:613–616

    Article  CAS  PubMed  Google Scholar 

  18. Boström PA, Fernández-Rea JM, Mantzoros CS (2014) Irisin in humans: recent advances and questions for future research. Metabolism 63:178–180

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

ADA has received lecture fees and research grant from Amgen and lecture fees from Lilly; SAP has received research grant from Amgen; PM has received lecture fees and research grants from Amgen and lecture fees from Glaxo, Lilly; AG, IB, AK, AF, and CSM have nothing to declare.

Neither Amgen nor Lilly had any influence on any stage of this study (study’s design, analysis and interpretation of data, drafting, or revising the manuscript).

Author information

Authors and Affiliations

  1. Department of Endocrinology, 424 General Military Hospital, Ring Road, 564 29 N. Efkarpia, Thessaloniki, Greece

    A. D. Anastasilakis

  2. Department of Medicine, Second Medical Clinic, Ippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

    S. A. Polyzos

  3. Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece

    P. Makras

  4. Department of Obstetrics and Gynaecology, 424 General Military Hospital, Thessaloniki, Greece

    A. Gkiomisi

  5. 2nd Department of Orthopaedics, 424 General Military Hospital, Thessaloniki, Greece

    I. Bisbinas

  6. Hellenic Military School of Medicine, Thessaloniki, Greece

    A. Katsarou

  7. Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    A. Filippaios & C. S. Mantzoros

Authors
  1. A. D. Anastasilakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. A. Polyzos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Makras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Gkiomisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Bisbinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Katsarou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Filippaios
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. S. Mantzoros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. D. Anastasilakis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anastasilakis, A.D., Polyzos, S.A., Makras, P. et al. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos Int 25, 1633–1642 (2014). https://doi.org/10.1007/s00198-014-2673-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-2673-x

Keywords

Search

Navigation